SG11202007739XA - Arginase inhibitors and methods of use thereof - Google Patents

Arginase inhibitors and methods of use thereof

Info

Publication number
SG11202007739XA
SG11202007739XA SG11202007739XA SG11202007739XA SG11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA SG 11202007739X A SG11202007739X A SG 11202007739XA
Authority
SG
Singapore
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
SG11202007739XA
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Jianyan Wang
Steve Cook
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202007739XA publication Critical patent/SG11202007739XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007739XA 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof SG11202007739XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202007739XA true SG11202007739XA (en) 2020-09-29

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007739XA SG11202007739XA (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Country Status (22)

Country Link
US (3) US11420984B2 (es)
EP (1) EP3752251A1 (es)
JP (2) JP7317841B2 (es)
KR (1) KR102657919B1 (es)
CN (3) CN117186134A (es)
AU (2) AU2019221896B2 (es)
BR (1) BR112020015973A2 (es)
CA (1) CA3091365A1 (es)
CL (1) CL2020002096A1 (es)
CR (1) CR20200418A (es)
DO (1) DOP2020000145A (es)
EC (1) ECSP20058183A (es)
IL (1) IL276711B1 (es)
JO (1) JOP20200197A1 (es)
MA (1) MA51837A (es)
MX (1) MX2020008570A (es)
NI (1) NI202000055A (es)
PE (1) PE20210176A1 (es)
SG (1) SG11202007739XA (es)
TW (1) TWI803574B (es)
UY (1) UY38096A (es)
WO (1) WO2019159120A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38096A (es) * 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
SG11202101618PA (en) 2018-08-22 2021-03-30 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
JP2023500506A (ja) * 2019-11-04 2023-01-06 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101931822B1 (ko) * 2010-04-22 2018-12-24 마아즈, 인코오포레이티드 아르기나아제의 억제제와 그것의 치료적 적용
EP3034509B1 (en) 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
JP6152167B2 (ja) 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
EA201890113A1 (ru) 2015-06-23 2018-07-31 Калитера Байосайенсиз, Инк. Композиции и способы ингибирования активности аргиназы
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3538111B1 (en) * 2016-11-08 2022-01-19 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
PT3559009T (pt) 2016-12-22 2021-05-04 Calithera Biosciences Inc Composições e métodos para inibir a atividade da arginase
WO2019120296A1 (en) 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
UY38096A (es) * 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
IL276711B1 (en) 2024-02-01
BR112020015973A2 (pt) 2020-12-15
AU2022203938A1 (en) 2022-06-23
WO2019159120A1 (en) 2019-08-22
US20210002305A1 (en) 2021-01-07
EP3752251A1 (en) 2020-12-23
IL276711A (en) 2020-09-30
ECSP20058183A (es) 2020-10-30
JP7317841B2 (ja) 2023-07-31
US11912727B2 (en) 2024-02-27
AU2022203938B2 (en) 2024-02-01
MA51837A (fr) 2021-06-16
AU2019221896B2 (en) 2022-03-24
TW201945004A (zh) 2019-12-01
PE20210176A1 (es) 2021-01-29
US20230365599A1 (en) 2023-11-16
CN117186134A (zh) 2023-12-08
TWI803574B (zh) 2023-06-01
UY38096A (es) 2019-07-31
CN117180290A (zh) 2023-12-08
DOP2020000145A (es) 2020-09-15
MX2020008570A (es) 2020-09-21
AU2019221896A1 (en) 2020-10-01
CR20200418A (es) 2020-10-27
NI202000055A (es) 2021-06-22
CA3091365A1 (en) 2019-08-22
NZ767738A (en) 2023-12-22
JP2023145557A (ja) 2023-10-11
JOP20200197A1 (ar) 2020-08-16
CN111712302A (zh) 2020-09-25
JP2021513964A (ja) 2021-06-03
CN111712302B (zh) 2023-09-19
US20230122859A1 (en) 2023-04-20
US11420984B2 (en) 2022-08-23
KR102657919B1 (ko) 2024-04-15
CL2020002096A1 (es) 2020-12-18
KR20200122341A (ko) 2020-10-27

Similar Documents

Publication Publication Date Title
EP3700527A4 (en) PAPD5 INHIBITORS AND THEIR METHODS OF USE
IL276711A (en) Arginase inhibitors and methods of using them
IL287940A (en) fgfr inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL283592A (en) Apol1 inhibitors and methods of using them
IL287768A (en) kcnt1 inhibitors and methods of use
IL287751A (en) kcnt1 inhibitors and methods of use
EP3765006A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL287973A (en) acss2 inhibitors and methods of their use
IL284640A (en) PCSK9 inhibitors and methods of using them
EP3810615A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL284661A (en) pcsk9 inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3897622A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
IL278989A (en) MASP-2 suppressors and methods of using them
IL280924A (en) Arginase inhibitors and methods of using them
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
EP3846808A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL286149A (en) Caspase inhibitors and methods of using them
IL286485A (en) pi4-kinase inhibitors and methods of using them
EP3793552C0 (en) ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF
IL285108A (en) Arginase inhibitors and methods of using them
EP4077332A4 (en) LIN28 INHIBITORS AND THEIR METHODS OF USE
EP3787630A4 (en) FERROCHELATASE INHIBITORS AND METHODS OF USE